Zosano Pharma, Inc. Announces Publication of Positive Phase 2 Study of Its ZP-PTH Patch for Osteoporosis Therapy
11/9/2009 9:33:48 AM
FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-delivery transdermal patch (ZP-PTH) for the treatment of postmenopausal osteoporosis. The study by authors Felicia Cosman, Nancy E. Lane, Michael A. Bolognese, Jose R. Zanchetta, Pedro A. Garcia-Hernandez, Karen Sees, James A. Matriano, Kim Gaumer, and Peter E. Daddona is titled “Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women.” The article is currently available online and will be in the January 2010 issue.